Azurity Pharmaceuticals is recalling its ADHD and narcolepsy drug Zenzedi nationwide, even as the U.S. faces a drug shortage.
Utah Senator who backed Orphan Drug Act will not seek reelection; medicines more expensive in 2018; Spark’s genetic therapy for rare blindness costs $850,000
The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers
The regulator has already issued more recalls in the first half of 2014 than it has over the past nine years.
The new rules are expected to do away with the haphazard nature of facility inspections.
It’s the generics maker’s second recall of 2014.
The drugmaker is pulling its US marketing application for the anemia drug.
The US-only recall amounts to less than 1% of the company’s inventory.
The company beat consensus estimates, with particular sales strengths from its pharmaceuticals division.
1,100 workers will lose their jobs at a plant with a history of around 40 recalls.
MM+M Transform: The Patient, Provider and Payer Engagement Matrix provides the most in-depth look at the marketing and technology trends likely to influence the industry’s growth over the next year.
Get the most out of
Register for free and enjoy unlimited access to: